Abstract
Interferon (IFN) therapy has been used for the treatment of common diseases such as hepatitis C, myeloproliferative disorders, autoimmune diseases and various types of cancer. Given the biological properties of interferon, it is not surprising that there are a larger number of side effects due to its use. Although rheumatoid arthritis (RA) is one of the most common autoimmune diseases found in clinical practice, it does not seem to be frequently related to IFN therapy. We report a 40-year-old female patient who, after high doses of IFN-α therapy for malignant melanoma, developed symmetrical polyarthritis, with pain and oedema in small and large joints, associated with prolonged morning stiffness. She had positive rheumatoid factor and DR4 HLA phenotype. She was treated with deflazacort (6 mg/day), chloroquine and NSAIDs, with a partial response. In conclusion, although the development of RA after IFN therapy is a rare event, IFN may work as a ‘trigger’ for such complication, leading to deregulation in the immune cascade in a person genetically predisposed.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 20 October 2000 / Accepted: 31 January 2001
Rights and permissions
About this article
Cite this article
Passos de Souza, E., Teles Evangelista Segundo, P., Freire José, F. et al. Rheumatoid Arthritis Induced by α-Interferon Therapy. Clin Rheumatol 20, 297–299 (2001). https://doi.org/10.1007/PL00011206
Published:
Issue Date:
DOI: https://doi.org/10.1007/PL00011206